Document:

Addendum No. 2 to Amended and Restated Master Services Agreement

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF
THE SECURITIES ACT OF 1933, AS AMENDED. 
 EXHIBIT 10.35 
 ADDENDUM No. 2 TO 
 AMENDED AND RESTATED MASTER SERVICES AGREEMENT 
 This Addendum No. 2 (the “Addendum”) to the AMENDED AND RESTATED MASTER SERVICES AGREEMENT dated as of May 31, 2005, as amended (collectively, the “Agreement”), by and between EXPRESS SCRIPTS
SPECIALTY DISTRIBUTION SERVICES, INC. (“ESSDS”) and ORPHAN MEDICAL, INC. (“Orphan Medical”) and assigned to JAZZ PHARMACEUTICALS, INC. (“Jazz Pharmaceuticals”), is
entered into as of the 22nd day of June, 2006 (the “Effective Date”) by and between ESSDS and
Jazz Pharmaceuticals. Capitalized terms not otherwise defined herein shall have the same meanings as in the Agreement. 
 RECITALS

 WHEREAS, Jazz Pharmaceuticals desires ESSDS to provide certain Nursing Program Services (as defined in Section 2 of
this Addendum) as a trial pilot program for its product, Xyrem, and related PAP; and 
 WHEREAS, the parties desire to include and
describe in more detail the provision by ESSDS of certain Nursing Program Services as a trial pilot program under the PAP to Jazz Pharmaceuticals as described herein; and 
 WHEREAS, Section 10.10 of the Agreement provides that the Agreement may be amended by a written instrument signed by both parties; and

 WHEREAS, the parties desire to supplement the Agreement as provided herein. 
 NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein and in
the Agreement, the parties hereto agree as follows: 
 AGREEMENT 
 1. Incorporation of Recitals. The Recitals are hereby incorporated into the Addendum. 
 2. Definitions. As used in this Addendum, the following term (and the plural thereof, when appropriate) shall have the meaning set forth
herein, except where the context makes it clear that such meaning is not intended: 
  

	 	a.	“Nursing Program Services” shall mean those services set forth in Exhibit A, attached hereto and incorporated herein by reference that are

  

 1. 

	 	b.	provided as a trial pilot program for the Jazz Pharmaceutical product, Xyrem and related PAP. 

  

	 	c.	Capitalized terms used herein but not defined herein shall have the meaning ascribed to them in the Agreement. 

 3. Performance of Nursing Program Services. ESSDS shall perform the Nursing Program Services set forth in Exhibit A as a trial pilot
program for Jazz Pharmaceuticals for its product, Xyrem and related PAP. ESSDS agrees to perform such Nursing Program Services with due care in accordance with the standards and practices which are generally accepted in the industry and exercised by
other persons engaged in performing similar services in the local area and in accordance with all applicable federal and state laws and regulations. In the event the pilot program is transitioned into a permanent program under the PAP, the parties
agree to renegotiate, in good faith, an agreement under which Nursing Program Services will be provided as a permanent program under the PAP. 
 4. Term and Termination. The term of this Addendum shall commence on the Effective Date, and continue through November 30, 2006, unless this Addendum is earlier terminated as provided herein or extended by the parties.
Either party may terminate this Addendum on thirty (30) days’ prior written notice to the other party, provided, however, that neither party may terminate this Addendum prior to August 31, 2006. 
 5. Fees. Jazz Pharmaceuticals shall pay ESSDS the fees described in Exhibit B in consideration of the performance of Nursing
Program Services. The fees described on Exhibit B shall constitute full and complete payment for performance of the Nursing Program Services by ESSDS under the Agreement. 
 6. Miscellaneous. 
  

	 	a.	Except as expressly set forth in this Addendum, all of the terms and conditions of the Agreement shall remain in full force and effect. 

  

	 	b.	To the extent there is a conflict between the terms and conditions of this Addendum and the terms and conditions of the Agreement, this Addendum shall control.

  

	 	c.	This Addendum may be executed in one or more counterpart copies, each of which shall be deemed an original, and all of which shall together be deemed to constitute one agreement.
Facsimile execution and delivery of this Addendum is legal, valid and binding execution and delivery for all purposes. 

 {SIGNATURE PAGE FOLLOWS} 
  

 2. 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED. 

 IN WITNESS WHEREOF, the parties have executed or
caused this Addendum to be executed as of this 22nd day of June, 2006. 
  

									
	 EXPRESS SCRIPTS SPECIALTY
 DISTRIBUTION
SERVICES, INC.
	 		 	JAZZ PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Gerard A. Carino
	 		 	By:	 	 /s/ Janne L. T. Wissel

	Its:	 	President PBS & SDS	 		 	Its:	 	SR VP Development

  

 3. 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED. 

 EXHIBIT A 
 NURSING PROGRAM SERVICES 
 Population 
  

	 	·	 	 Patients to whom Nursing Program Services will be offered under the trial pilot program (the “pilot patient population”) will include all new enrollees on
a given day of the week (e.g., every Tuesday or such other day as determined by the parties) over a recommended period of [ * ]. 

 Contact 
  

	 	·	 	 ESSDS nurses will contact a random, select group of the pilot patient population at designated intervals over the course of the first 90 days of such
individual’s Xyrem therapy. There will be [ * ] “touch points” with the patient through the [ * ] refill: [ * ] 

 The patient may contact the nurse at other intervals throughout the pilot program. Additionally, it may be necessary for the nurse to contact the patient’s physician throughout the pilot program for clarification
of orders and/or compliance issues. 
 Documentation 
  

	 	·	 	 ESSDS will document all contact with the patients selected from the pilot patient population and their physicians’ offices. 

 Reporting 
  

	 	·	 	 ESSDS will provide a monthly report to include patient [ * ]. 

 Program Continuation 
  

	 	·	 	 Outcomes for improvement in length of therapy will be measured and reported to determine whether permanent PAP program-wide implementation should occur.

  

 A-1 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED. 

 EXHIBIT B 
 FEES 
  

			
	 Services
	  	Fees
	 Monthly Management Fee (prorated for partial months)
	  	$[ * ]

 The fee schedule listed above is subject to the following qualifications: 
  

	 	·	 	 The fees apply to the Nursing Program Services only. 

  

	 	·	 	 In the event the Nursing Program Services are canceled and this Addendum terminated, the nursing staff will continue to contact patients through the [ * ]
refill. 

  

	 	·	 	 SDS will be paid the Monthly Management Fee each month until all patients have cycled through the [ * ] refill. 

  

	 	·	 	 Pricing will be re-evaluated upon permanent program-wide implementation. 

  

 B-1 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.Addendum No. 3 to Amended and Restated Master Services Agreement

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF
THE SECURITIES ACT OF 1933, AS AMENDED. 
 EXHIBIT 10.36 
 ADDENDUM No. 3 
 TO AMENDED AND RESTATED MASTER SERVICES AGREEMENT 
 THIS ADDENDUM NO. 3 TO AMENDED AND RESTATED MASTER SERVICES AGREEMENT (this “Addendum”) is entered into as of the 17th day of August, 2006 (the “Effective Date”) by and between Express Scripts Specialty Distribution Services, Inc. (“SDS”) and Jazz Pharmaceuticals, Inc.

 RECITALS 
 WHEREAS, this
Addendum relates to and is hereby incorporated into the Amended and Restated Services Agreement between Express Scripts Specialty Distribution Services, Inc. and Orphan Medical, Inc., dated May 31, 2005, which was effective as of
January 1, 2005, as assigned to Jazz Pharmaceuticals, Inc., together with the Consent and Addendum dated June 1, 2006 and the Addendum No. 2 dated June 22, 2006 (hereinafter collectively referred to as the “Agreement”);
and 
 WHEREAS, the NDC code for Xyrem (the “Product”) has been changed due to the change in marketing company from Orphan Medical, Inc. to
Jazz Pharmaceuticals, Inc.; and 
 WHEREAS, Jazz Pharmaceuticals, Inc. is awaiting a rebate agreement acceptance (“Acceptance”) from Centers
for Medicare and Medicaid Services (“CMS”) which would provide rebates for the Product under the new NDC code (“New Lot”); and 
 WHEREAS, Jazz Pharmaceuticals, Inc. desires SDS to provide to Medicaid Patients (as defined below) the Product under the prior NDC code (“Prior Lot”), as opposed to the New Lot, until such Acceptance is completed; and

 WHEREAS, Article 1, Additional Services, allows additional services to be incorporated into the Agreement through use of an Additional Services
Request Form as described on Exhibit D of the Agreement; and 
 WHEREAS, the parties desire to supplement the Agreement through this Addendum.

 NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein and in
the Agreement, the parties hereto agree as follows: 
 AGREEMENT 
 1. Incorporation of Recitals. The Recitals are hereby incorporated into the Addendum. 
 2. Interim Management of Medicaid Patients. SDS shall provide the Prior Lot to Medicare Patients (as defined below) as further detailed below
(“Additional Services”). 

  

 1. 

 
SDS will manage and provide the Covered Services, described in the Agreement and on Exhibit A of the Agreement, for the specific provision, to Non-PAP
Patients who have Medicaid coverage and are approved by Medicaid to receive the Product (“Medicaid Patients”), of the Prior Lot, as opposed to the New Lot, until such time as notification is received from Jazz Pharmaceuticals, Inc. that
the Acceptance is finalized. Additional Services will require SDS to perform system program changes to ensure the accuracy of selection and provision of the Prior Lot for this particular group of Patients. In addition, the SDS operations team will
need to develop the processes necessary and train staff to effectively transition the Medicaid Patients, These programming changes will have an impact on reporting, purchase orders, inventory management and other associated program aspects.

 3. Fees for Additional Services: 
 a. A one time $[ * ] set up fee. 
 b. Medicaid Patients will be billed at $[ * ] per order
for shipments from the Prior Lot to such patients. 
 IN WITNESS HEREOF, the parties have executed or caused this Addendum to be executed as of the
date indicated above. 
  

							
	 EXPRESS SCRIPTS SPECIALTY
 DISTRIBUTION SERVICES, INC.
	 	JAZZ PHARMACEUTICALS, INC.
				
	By:	 	 /s/ Gerard A. Carino
	 	By:	 	 /s/ Carol Gamble

	Name:	 	Gerard A. Carino	 	Name:	 	Carol Gamble
	Title:	 	President, PBS & SDS	 	Title:	 	Sr. Vice President & General Counsel

  

 2. 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]